Ibutilide Fumarate Injection launched

Download PDF Copy

Jan 12 2010

NewsGuard 100/100 Score

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert® from Pfizer Inc.

"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.

This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.

SOURCE Bioniche Pharma

Posted in: Pharmaceutical News

Tags: Atrial Fibrillation, Chronic, Pharmaceuticals

Comments (0)

Download PDF Copy

Suggested Reading

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Obesity crisis in the U.S. expected to worsen by 2050